Compare Illinois Tool Works Inc. (ITW) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illinois Tool Works Inc. vs Summit Therapeutics Inc — how do they compare? Illinois Tool Works Inc. trades at $293.28 (market cap $83.49B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Illinois Tool Works Inc. is far larger — about 6.9× Summit Therapeutics Inc's market cap, and Illinois Tool Works Inc. pays a 2.35% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ITW | SMMT | |
|---|---|---|
Market Cap | $83.49B | $12.06B |
Sector | Industrials | Health |
52-Week High | $299.60 | $26.98 |
52-Week Low | $241.07 | $12.55 |
Enterprise Value | $92.34B | $11.39B |
Dividend Yield | 2.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ITW trades at $292.54, down 0.67% on the day, with a bullish technical signal and strong fundamentals including a 19.39% net income margin and consistent earnings beats. Recent news highlights a 7% dividend increase and a $6 billion share repurchase program, reflecting management confidence. The stock is near key support at $290 with resistance at $300.
Outlook is positive due to robust profitability and shareholder returns, but risks include high valuation multiples and debt levels. Analyst consensus is mixed with a $314.25 price target, suggesting moderate upside potential amid cautious sentiment from some institutional sellers.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
